Vertex Pharmaceuticals (VRTX) Restructuring Costs (2009 - 2018)
Vertex Pharmaceuticals' quarterly Restructuring Costs came in at -$4000.0 in Q4 2018, down 101.03% year-on-year from $387000.0 in Q4 2017, and down 102.3% quarter-over-quarter from $174000.0 in Q3 2018.
Vertex Pharmaceuticals has reported Restructuring Costs for 10 years, with the latest figure at -$4000.0 in Q4 2018.
- For the quarter ending Q4 2018, Restructuring Costs fell 101.03% year-over-year to -$4000.0; the trailing twelve-month figure through Sep 2019 stood at -$4000.0 (down 100.7% YoY), and the FY2018 full-year result was -$184000.0, down 101.29% from the prior year.
- Restructuring Costs for Q4 2018 stood at -$4000.0, down from $174000.0 in the prior quarter.
- The five-year high for Restructuring Costs was $40.8 million in Q3 2014, with the low at -$3.3 million in Q1 2015.
- Average Restructuring Costs over 5 years is $3.4 million, with a median of $365000.0 recorded in 2016.
- Year-over-year, Restructuring Costs soared 15766.67% in 2014 and slumped 152.88% in 2015.
- Tracing VRTX's Restructuring Costs over 5 years: stood at $4.2 million in 2014, then sank by 63.4% to $1.5 million in 2015, then tumbled by 85.3% to $224000.0 in 2016, then surged by 72.77% to $387000.0 in 2017, then slumped by 101.03% to -$4000.0 in 2018.
- The last three Restructuring Costs figures came in at -$4000.0 (Q4 2018), $174000.0 (Q3 2018), and -$62000.0 (Q2 2018), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Revolution Medicines | 31.20 Bn | 31.20 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | -4,000.00 |
| Sep 30, 2018 | 174,000.00 |
| Jun 30, 2018 | -62,000.00 |
| Mar 31, 2018 | 76,000.00 |
| Dec 31, 2017 | 387,000.00 |
| Sep 30, 2017 | 337,000.00 |
| Jun 30, 2017 | 3.52 Mn |
| Mar 31, 2017 | 10.00 Mn |
| Dec 31, 2016 | 224,000.00 |
| Sep 30, 2016 | 8,000.00 |
| Jun 30, 2016 | 343,000.00 |
| Mar 31, 2016 | 687,000.00 |
| Dec 31, 2015 | 1.52 Mn |
| Sep 30, 2015 | 1.83 Mn |
| Jun 30, 2015 | 2.13 Mn |
| Mar 31, 2015 | -3.27 Mn |
| Dec 31, 2014 | 4.16 Mn |
| Sep 30, 2014 | 40.84 Mn |
| Jun 30, 2014 | -270,000.00 |
| Mar 31, 2014 | 6.19 Mn |
| Dec 31, 2013 | 27.66 Mn |
| Sep 30, 2013 | 12.05 Mn |
| Jun 30, 2013 | 776,000.00 |
| Mar 31, 2013 | 39,000.00 |
| Dec 31, 2012 | 194,000.00 |
| Sep 30, 2012 | 696,000.00 |
| Jun 30, 2012 | 594,000.00 |
| Mar 31, 2012 | 360,000.00 |
| Dec 31, 2011 | 992,000.00 |
| Sep 30, 2011 | -419,000.00 |
| Mar 31, 2011 | 760,000.00 |
| Dec 31, 2010 | -2.26 Mn |
| Sep 30, 2010 | 866,000.00 |
| Jun 30, 2010 | 2.11 Mn |
| Mar 31, 2010 | 780,000.00 |
| Dec 31, 2009 | 1.96 Mn |
| Sep 30, 2009 | 774,000.00 |
| Jun 30, 2009 | 1.11 Mn |
| Mar 31, 2009 | 2.40 Mn |